viewYellow Cake PLC

Yellow Cake’s uranium holdings increase by US$29.3mln in latest half year

The increase was attributed to a US$30.4mln uranium purchase during the six months, while the company estimated NAV stood at 232p per share

Yellow Cake PLC - Yellow Cake’s uranium holdings increase by US$29.3mln in latest half year

Yellow Cake PLC (LON:YCA) has seen the value of its uranium holdings increase by US$29.3mln in its latest half-year.

The value of the firm’s uranium holdings rose to US$246.7mln in the six months to 30 September, attributed to a US$30.4mln uranium purchase being slightly offset by a US$1.1mln loss in the period.

READ: Yellow Cake considers share buy-backs as uranium market remains subdued

As a result, the company’s estimated net asset value at the end of the six months was 232p per share, while it also reported a net loss after tax of US$3.1mln.

Looking ahead, Yellow Cake’ chief executive Andre Liebenberg said the company is currently awaiting the conclusion of the US Nuclear Fuel Working Group's investigations into the US nuclear fuel industry, which they expected to “bring to an end a long period of uncertainty that has significantly slowed activity in the traded uranium market which has subsequently weighed heavily on the uranium price”.

He added that the company is still considering the option of a share buyback so it can “acquire additional exposure to uranium at a discount to the spot price”.

In early trading on Thursday, Yellow Cake shares were 0.8% higher at 194.6p.

Quick facts: Yellow Cake PLC

Price: 190.47886 GBX

Market: AIM
Market Cap: £167.44 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Sareum Holdings new licensing deal 'could generate significant near-term...

Sareum Holdings PLC's (LON:SAR) Tim Mitchell speaks to Proactive's Andrew Scott soon after announcing a licensing deal with an unnamed Chinese specialty pharmaceutical company. The firm will develop Sareum's FLT3+Aurora kinases portfolio, including SAR-20293, a preclinical drug candidate for...

1 hour, 33 minutes ago

2 min read